0 patents currently held, every record listed here
9 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
This portfolio holds none of the 9 US patents in force on its record. from the record
Of the 9 now held by other companies, 9 name Tolmar Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
none
Next term end
When these terms end
Each bar runs from grant to computed term end. 2012 to 2039.
US 11,331,325
Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same
Jan 6, 2027
US 8,241,664
Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Compositions Comprising Same
Mar 29, 2029
US 8,778,916
Oral Testosterone Ester Formulations and Methods of Treating Testosterone Deficiency Comprising Same
Apr 12, 2030
US 10,617,696
Oral Testosterone Ester Formulations and Methods of Treating Testosterone Deficiency Comprising Same
Apr 12, 2030
US 10,543,219
Oral Testosterone Ester Formulations and Methods of Treating Testosterone Deficiency Comprising Same
Apr 12, 2030
US 11,179,403
Oral Testosterone Ester Formulations and Methods of Treating Testosterone Deficiency Comprising Same
Apr 12, 2030
US 11,426,416
Oral Testosterone Ester Formulations and Methods of Treating Testosterone Deficiency Comprising Same
Apr 12, 2030
US 10,245,273
Oral Pharmaceutical Products and Methods of Use Combining Testosterone Esters with Hypolipidemic Agents
Dec 24, 2034
20182024203020362039
1 pending application: term is not computable until grant.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
None of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Mar 2029 · High confidence
The most cited patent in this portfolio, cited by 178 later US patents, top 5% of utility patents granted in 2012 in our data. Protection runs to 2029.
now held by Tolmar, Inc.
Also notable
Ends Apr 2030 · High confidence
Cited by 13 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
now held by Tolmar, Inc.
Also notable
Ends Dec 2034 · High confidence
Cited by 15 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2034.
now held by Tolmar, Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first.
Also on record: 9 patents in force now held by others · 3 patents ended · 1 application pending · 22 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.